Latest Financial Audits News

Grange Resources has reported a notable decline in profits for the 2025 financial year, alongside an 8% fall in revenues and no dividend payout, signaling a cautious stance amid challenging conditions.

DGL Group Limited has outlined a clear path to regain its ASX listing following suspension, targeting reinstatement by February or March 2026 pending audit outcomes.

Energy World Corporation’s final audited results for FY25 reveal a major loan-to-equity reclassification and a reshuffle of director fee liabilities, reshaping the company’s balance sheet.

Vinyl Group Ltd reported a striking 190% revenue increase for FY2025 but remains deep in the red with a $15.8 million loss. The company’s recent acquisitions and ongoing audit spotlight a pivotal moment for its future.

Careteq Limited reported a dramatic reduction in its FY25 loss to just $72,204, down from $2.67 million the prior year, while facing a significant $3.6 million dispute with the Australian Taxation Office over R&D tax claims.

BDO Audit has completed its review of HeraMED Limited’s half-year financial report for June 2025, confirming compliance with accounting standards but highlighting significant uncertainty over the company’s ability to continue as a going concern.

ImpediMed Limited has posted a 23% increase in revenue for the 2025 financial year, yet its net loss widened by 17%, with no dividends declared. The company’s financials, audited by Ernst & Young, reveal a complex picture of growth paired with escalating costs.

IGO Limited has reported a dramatic downturn in its financial results for the year ended June 2025, with revenue plunging 60% and a net loss nearing $1 billion. The company also suspended dividends as net tangible assets per share fell sharply.

Noumi Limited has posted a significant $150 million loss for the year ending June 2025, driven by non-cash charges and raising questions about its financial stability.

Adisyn Ltd has made significant strides in developing low-temperature graphene semiconductor interconnects, commissioning a new Atomic Layer Deposition system and securing a major managed IT services contract, while maintaining a strong cash position.

Advanced Health Intelligence has been formally delisted from NASDAQ due to shareholder equity deficiencies but is actively pursuing ASX reinstatement as a critical step toward regaining its dual-listing status.

Adisyn Ltd has successfully completed a key R&D program on low-temperature graphene deposition, earning full approval and final payment of a $520,000 grant from the Israel Innovation Authority. This milestone validates its cutting-edge semiconductor technology aimed at revolutionizing AI and high-performance computing.